Total submissions: 11
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000080359 | SCV000112255 | benign | not specified | 2013-08-20 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV000080359 | SCV000309906 | benign | not specified | criteria provided, single submitter | clinical testing | ||
Labcorp Genetics |
RCV001514012 | SCV001721749 | benign | Renal coloboma syndrome; Focal segmental glomerulosclerosis 7 | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001711236 | SCV001946311 | benign | not provided | 2015-03-03 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001787886 | SCV002029384 | benign | Focal segmental glomerulosclerosis 7 | 2021-09-05 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000608368 | SCV002029385 | benign | Renal coloboma syndrome | 2021-09-05 | criteria provided, single submitter | clinical testing | |
Unidad de Genómica Garrahan, |
RCV000080359 | SCV005087937 | benign | not specified | 2024-07-15 | criteria provided, single submitter | clinical testing | This variant is classified as Benign based on local population frequency. This variant was detected in 97% of patients studied in a panel designed for Epileptic and Developmental Encephalopathy and Progressive Myoclonus Epilepsy. Number of patients: 90. Only high quality variants are reported. |
Breakthrough Genomics, |
RCV001711236 | SCV005320037 | benign | not provided | criteria provided, single submitter | not provided | ||
Diagnostic Laboratory, |
RCV000608368 | SCV000732902 | benign | Renal coloboma syndrome | no assertion criteria provided | clinical testing | ||
Genome Diagnostics Laboratory, |
RCV000080359 | SCV001928005 | benign | not specified | no assertion criteria provided | clinical testing | ||
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV000080359 | SCV001959205 | benign | not specified | no assertion criteria provided | clinical testing |